Neumora Reveals Mid-Stage Data For Fully Funded, Phase III-Ready Depression Drug

Private Biotech Has Raised $650m To Date

Neumora’s once-daily oral kappa opioid receptor (KOR) antagonist navacaprant succeeded in a Phase II trial and will move into the first of three Phase III studies soon, with a US filing targeted for 2025.

Fear, loneliness, depression, abuse, addiction
Neumora's navacaprant aims to treat anhedonia, an inability to experience pleasure or joy, in depression patients • Source: Shutterstock

Privately held Neumora Therapeutics, Inc. has one well-funded rival in the late-stage development of a kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD), but as the company moves its drug candidate navacaprant (NMRA-140) into Phase III this year, it also has its own deep well of cash to execute its pivotal trials and a slightly different approach to the MDD market than Johnson & Johnson has taken with its Phase III KOR antagonist aticaprant.

Neumora was founded in 2019 to develop precision medicines for neuropsychiatric and neurodegenerative diseases, and came out of stealth mode in 2021 with more than $400m in series A venture capital plus $100m provided by Amgen, Inc., from which the start-up licensed a pair of preclinical drug candidates

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D